FibroBiologics, Inc. (FBLG)
NASDAQ: FBLG · IEX Real-Time Price · USD
11.35
-0.45 (-3.81%)
May 17, 2024, 4:30 PM EDT - Market closed
FibroBiologics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
10
Market Cap
371.03M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 0 | - | - |
Dec 31, 2022 | 0 | - | - |
Dec 31, 2021 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionFBLG News
- 3 days ago - FibroBiologics Announces 2024 Annual Meeting of Stockholders - GlobeNewsWire
- 4 days ago - FibroBiologics Files 2024 First Quarter Report - GlobeNewsWire
- 11 days ago - FibroBiologics to Present at the BIO International Convention 2024 - GlobeNewsWire
- 5 weeks ago - FibroBiologics Granted Patent for Regeneration of Cartilage-Type Cells by the Australian Patent Office - GlobeNewsWire
- 6 weeks ago - FibroBiologics Presents Data from Dermal Fibroblast Spheroid-based Treatment of Chronic Wounds in a Diabetes Mouse Model at Advanced Wound Care Summit USA - GlobeNewsWire
- 7 weeks ago - FibroBiologics Files Patent Application Covering Fibroblast-based Technology for the Potential Treatment of Lupus - GlobeNewsWire
- 2 months ago - FibroBiologics Announces Preliminary Proof of Concept for Fibroblast-based Diabetes Treatment - PRNewsWire
- 2 months ago - FibroBiologics to Present at Advanced Wound Care Summit USA - PRNewsWire